ofa semaglutide lawsuit Novo Nordisk is suing U.S. telehealth company Hims and Hers, alleging patent infringement over its planned release of a knockoff version of its Wegovy weight loss pill. Hims and Hers is pushing back, The FDA Wins. The OFA

And there still isnt much in the way of human data

Tirzepatide Research Overview Built as a dual GIP and GLP-1 receptor agonist, Tirzepatide is extensively studied for its influence on metabolism, appetite regulation, and glucose balance

GLP-1s May Help With Increased hunger related to metabolic imbalance Ongoing cravings that interfere with healthy eating patterns Difficulty losing weight despite consistent nutrition and exercise Metabolic concerns associated with insulin resistance Overeating tied to disrupted hunger and fullness signaling Potential Benefits of GLP-1 Therapy Decreased hunger and better control over cravings More stable blood sugar levels that may help support steady energy Improved satiety signals to assist with portion control Gradual, medically supervised weight loss without stimulants Improved metabolic function supporting long-term goals A flexible dosing plan tailored to your individual response Reduced dependence on extreme dieting or intense exercise routines Greater ability to maintain consistent, healthy habits Our Personalized GLP-1 Program in Cumming Initial consultation Your first visit is focused on getting a complete picture of your health

Following approval, Rybelsus was gradually launched in markets worldwide, offering patients a needle-free alternative to injectable GLP-1s like Ozempic and Wegovy